Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Japanese chemical firms pursue diversification

by Jean-François Tremblay
September 12, 2016 | A version of this story appeared in Volume 94, Issue 36

Two Japanese chemical companies are advancing their diversification into biologic materials. Asahi Glass, a maker of glass and basic chemicals, is buying Bio­meva, a German contract manufacturer of microbially derived biopharmaceuticals. Founded in 1993, Biomeva operates fermentors with a production capacity of up to 1,000 L and counts major drug firms such as Takeda Pharmaceutical and Bayer among its customers. Asahi Glass is already one of the largest producers of microbially fermented biologics in Japan. Meanwhile, Fujifilm is acquiring a 10% stake in Cynata Therapeutics, an Australian developer of stem-cell-based regenerative medicines. Cynata is developing stem cells that can be used to treat age-related macular degeneration, Parkinson’s disease, and heart disease. Fuji­film made a big push into cellular technology last year with the $300 million purchase of Cellular Dynamics International.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.